CILP2: A prognostic biomarker associated with immune infiltration in colorectal cancer
Xueli Wang,
Yu Zhang,
Niping Song,
Kaiqiang Li,
Siyun Lei,
Jianwei Wang,
Zhen Wang,
Wei Zhang
Affiliations
Xueli Wang
College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310032, China
Yu Zhang
Department of Gastroenterology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China
Niping Song
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
Kaiqiang Li
Center for Laboratory Medicine, Allergy Center, Department of Transfusion Medicine, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China
Siyun Lei
College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310032, China
Jianwei Wang
College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310032, China
Zhen Wang
Center for Laboratory Medicine, Allergy Center, Department of Transfusion Medicine, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China; Corresponding author.
Wei Zhang
College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310032, China; Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, China; Corresponding author. Department of Gastrointestinal surgery, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, China.
Purpose: The function played by cartilage intermediate layer protein 2 (CILP2) between colorectal cancer (CRC) progression and immune response remains unclear, especially with respect to immune cell infiltration and checkpoints. Materials and Methods: We examined CILP2 expression in The Cancer Genome Atlas (TCGA) COAD-READ cohort and analyzed its relationship with clinicopathological features, mutations, survival, and immunity. Gene ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis, and gene set enrichment analyses (GSEA) were performed to determine CILP2 related pathways. To further investigate the results of TCGA analysis, validation was performed using CRC cell lines, fresh pathological tissues, and a CRC tissue microarray (TMA). Results: In both TCGA and TMA cohorts, CILP2 expression was increased in CRC tissues and was associated with patient T stage (T3 and T4), N stage (N1), pathological stage (III and IV), and overall survival. Immune cell infiltration and checkpoint analysis revealed that CILP2 expression is highly correlated with multiple immune marker genes, including PD-1. In addition, results of enrichment analysis indicated that CILP2 related genes was mainly enriched in extracellular matrix related functions. Conclusion: Elevated CILP2 expression is associated with adverse CRC clinical features and immune cells, it has potential as a biomarker detrimental to CRC survival.
